Ustekinumab Completed Phase 2 Trials for Atopic Dermatitis (AD) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01945086A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis
NCT01806662Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis